Search

Displaying results 6901 - 6910 of 7674 in total
  1. Drug

    Telenzepine

    go.drugbank.com/drugs/DB19508
    Investigational

    Telenzepine has a monoisotopic molecular weight of 370.15 Da.

  2. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton has a monoisotopic molecular weight of 463.12 Da.

  3. Drug

    Bamipine

    go.drugbank.com/drugs/DB13489
    Investigational

    Bamipine is a first-generation antihistamine.

  4. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  5. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.

  6. Drug

    MVR-T3011

    go.drugbank.com/drugs/DB17378
    Investigational

    MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1

  7. Drug

    Latrunculin A

    go.drugbank.com/drugs/DB02621
    Investigational

    Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer.

  8. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.

  9. Drug

    Inositol 1,3-bisphosphate

    go.drugbank.com/drugs/DB02942
    Experimental

    It is an experimental compound with no approved therapeutic indications. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural

  10. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.